Evidence map›Paper›PMID 41726992›Full record

ArticlebioRxiv : the preprint server for biology2026

PDE4 Inhibitor Apremilast Rebalances Inflammatory Responses to Pseudomonas aeruginosa Infection in CF Rats.

Linto Antony, Lawrence Rasmussen, Denise Stanford, Antonio Allen, Daniel Kennedy, Levi W Brewer, Aditi Shanbhag, Jennifer LaFontaine, S Vamsee Raju

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Linto AntonyCystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-8762-3299
Lawrence RasmussenCystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Denise StanfordCystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Antonio AllenDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Daniel KennedyDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Levi W BrewerDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Aditi ShanbhagDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Jennifer LaFontaineDivision of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
S Vamsee RajuCystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0003-3947-4871

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMIT GAGGAR · 2007 to 2026
$23.0M
Acquired CFTR Dysfunction in Alcohol-related Lung PathologyR01AA027528 · NIAAA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RAJU, S.VAMSEE · 2020 to 2024
$1.9M
Multi-parameter, analytic flow cytometerS10OD032296 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2022 to 2022
$464k
NCI NIH HHS P30 CA013148NIAAA NIH HHS R01 AA027528NIAID NIH HHS P30 AI027767NIDDK NIH HHS P30 DK072482NIH HHS S10 OD032296
6 · The paper itself

Abstract

CFTR modulator therapies have transformed CF care, yet chronic airway inflammation persists in many people with cystic fibrosis (pwCF) even after long-term highly effective modulator therapy (HEMT). Because of the adverse side effects or the incompatibility with CFTR modulators, the use of traditional anti-inflammatory therapies is very limited in CF. Hence, new therapeutic strategies that rebalance inflammation without worsening infection with immunosuppression are needed. We evaluated the selective phosphodiesterase 4 (PDE4) inhibitor apremilast (Apr) for its ability to modulate dysregulated inflammation in humanized CF (G551D) rats acutely challenged with

Identifiers

PMID41726992
PMCPMC12918811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.